Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases. Local targets link to admitted publications; unresolved targets remain external evidence.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
10.1016/s1470-2045(09)70025-7 · 2009 · External reference
Radiotherapy for glioblastoma in the elderly
10.1056/nejmoa065901 · 2007 · External reference
Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome
10.1016/j.semradonc.2005.08.007 · 2006 · External reference
Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A
10.1016/s1535-6108(03)00048-5 · 2003 · External reference
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents
10.1074/jbc.m300229200 · 2003 · External reference
Chk1 and Chk2 kinases in checkpoint control and cancer
10.1016/s1535-6108(03)00110-7 · 2003 · External reference
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
10.1016/j.molmed.2010.10.009 · 2011 · External reference
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer
10.1016/b978-0-12-380888-2.00003-0 · 2010 · External reference
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
10.1038/nature07385 · 2008 · External reference
Malignant astrocytic glioma: genetics, biology, and paths to treatment
10.1101/gad.1596707 · 2007 · External reference
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
10.1038/nature05236 · 2006 · External reference
Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study
10.1073/pnas.95.12.7012 · 1998 · External reference
Predicting and monitoring cancer treatment response with diffusion-weighted MRI
10.1002/jmri.22167 · 2010 · External reference
Molecular diffusion, tissue microdynamics and microstructure
10.1002/nbm.1940080711 · 1995 · External reference
Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging
1997 · External reference
Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging
10.1016/j.jvir.2007.04.025 · 2007 · External reference
Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases
10.1148/radiol.2483071407 · 2008 · External reference
Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas
10.1002/jmri.21358 · 2008 · External reference
Diffusion MRI for prediction of response of rectal cancer to chemoradiation
10.1016/s0140-6736(02)09520-x · 2002 · External reference
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
10.1158/1535-7163.mct-08-0492 · 2008 · External reference
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair
10.1158/0008-5472.can-09-3573 · 2010 · External reference
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma
10.1371/journal.pone.0035857 · 2012 · External reference
Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition
10.1158/1078-0432.ccr-10-3082 · 2011 · External reference
Dynamic imaging of emerging resistance during cancer therapy
10.1158/0008-5472.can-05-3205 · 2006 · External reference
Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy
10.1162/153535002321093945 · 2002 · External reference
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors
10.1093/jnci/92.24.2029 · 2000 · External reference
Quantitative 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: identification of apoptotic response
1998 · External reference
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies
10.1016/j.ymthe.2004.07.022 · 2004 · External reference
Monitoring thymidine kinase and ganciclovirinduced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging
1998 · External reference
Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy
10.1038/sj.gt.3301199 · 2000 · External reference
Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo
10.1038/bjc.1996.11 · 1996 · External reference
Applications of magnetic resonance in model systems: cancer therapeutics
10.1038/sj.neo.7900078 · 2000 · External reference
Diffusion MR imaging. Theory and applications
10.1016/s1052-5149(25)00563-5 · 1999 · External reference
Evaluationof the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma
10.1073/pnas.0508347102 · 2005 · External reference
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response
10.1073/pnas.0501532102 · 2005 · External reference
MGMT gene silencing and benefit from temozolomide in glioblastoma
10.1056/nejmoa043331 · 2005 · External reference
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
10.1038/nature03482 · 2005 · External reference
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1
10.1016/j.ccr.2009.12.020 · 2010 · External reference
Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53
10.1101/gad.14.3.278 · 2000 · External reference
hCds1mediated phosphorylation of BRCA1 regulates the DNA damage response
10.1038/35004614 · 2000 · External reference
In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762
10.1158/1078-0432.ccr-09-3277 · 2010 · External reference
Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1
10.4161/cc.10.24.18661 · 2011 · External reference
p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells
2001 · External reference
Cytotoxic effects of temozolomide and radiation are additive-and schedule-dependent
10.1016/j.ijrobp.2009.07.1703 · 2009 · External reference
Abrogation of the Chk1mediated G2 checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells
2001 · External reference
